SyntheticMR Q3 showed sales growth of -39% y/y, coming in 24% below expectations, as it continues to be held back by disruptions in North America communicated last quarter. The company says it expects gradual improvement in North America in Q4. EBIT excluding FX revaluation was -4.1m (cons -0.1m), although a bright spot was relatively good FCF (-3.3m). The report leads to 5% mechanical revisions to 2024 consensus EBIT.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.